Heart Failure Management Guidelines

Introduction to Heart Failure Stages

The American College of Cardiology recommends classifying heart failure into four progressive stages (A through D), with Stage A representing patients at risk but without structural disease, and Stage D representing refractory heart failure requiring specialized interventions 1
Patients with hypertension, atherosclerotic disease, diabetes mellitus, obesity, metabolic syndrome, family history of cardiomyopathy, or exposure to cardiotoxins are considered at high risk for heart failure 1

The American College of Cardiology recommends initiating four medication classes simultaneously for patients with symptomatic HFrEF: an SGLT2 inhibitor, a mineralocorticoid receptor antagonist (MRA), a beta-blocker, and an ARNI (or ACE inhibitor/ARB if ARNI not tolerated) 2
SGLT2 inhibitors, such as dapagliflozin 10 mg once daily or empagliflozin 10 mg once daily, reduce cardiovascular death and HF hospitalization regardless of diabetes status 2
Mineralocorticoid receptor antagonists, such as spironolactone 12.5-25 mg once daily or eplerenone 25 mg once daily, provide at least 20% mortality reduction and reduce sudden cardiac death 2
Beta-blockers, such as carvedilol, metoprolol succinate, or bisoprolol, reduce mortality by at least 20% and decrease sudden cardiac death 2
ARNI (sacubitril/valsartan) is preferred over ACE inhibitors and provides at least 20% mortality reduction 2

SGLT2 inhibitors (dapagliflozin or empagliflozin) are the cornerstone of HFpEF treatment, reducing cardiovascular death and HF hospitalization 3
Diuretics should be used judiciously as needed to reduce congestion and improve symptoms 3

The American College of Cardiology recommends targeting systolic blood pressure of 130 mmHg, but not less than 120 mmHg, to avoid worsening cardiac output in patients with hypertension and heart failure 4
SGLT2 inhibitors are the preferred diabetes medication in patients with heart failure, providing cardiovascular benefit regardless of baseline diabetes status 3

Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) are absolutely contraindicated in HFrEF as they increase the risk of worsening heart failure and hospitalization 2
Alpha-blockers (tamsulosin, doxazosin, terazosin, alfuzosin) should be avoided in patients with heart failure 2

Initial diagnostic workup should include complete blood count, urinalysis, serum electrolytes, blood urea nitrogen, serum creatinine, fasting blood glucose, lipid profile, liver function tests, and thyroid-stimulating hormone 1
Ongoing monitoring during GDMT optimization should include blood pressure, heart rate, renal function, and electrolytes at 1-2 weeks after each dose increment 2

Delaying initiation of all four medication classes simultaneously can lead to suboptimal treatment outcomes 2
Accepting suboptimal doses without attempting titration can result in reduced efficacy 2
Stopping medications for asymptomatic hypotension can lead to increased mortality risk 2

Patients with persistent NYHA class III-IV symptoms despite optimal GDMT, recurrent hospitalizations, need for continuous or intermittent inotropic support, or consideration for advanced therapies (mechanical circulatory support, transplantation) should be referred to a heart failure specialist 2